Table 1.
Summary table of the key studies involving injection of patient-derived tau fibrils in different mouse models.
| Tg Line | Tau Isoform | Tau Overexpression | Key Study | ||
|---|---|---|---|---|---|
| Wild-type mice | Mice expressing wild-type mouse tau | 4R | No | Lasagna-Reeves et al., 2012 Guo et al., 2016 Ferrer et al., 2018, 2019, 2020, 2020, 2020 Narasimhan et al., 2017 Henderson et al., 2020 |
|
| Tauopathy mouse models | Tg mice overexpressing human tau with FTD-linked mutation | PS19 (P301S MAPT mutation) | 4R | Yes | Boluda et al., 2015 |
| T40PL-GFP (P301L MAPT mutation + GFP) | 4R | Yes | Gibbons et al., 2017 | ||
| Tg mice overexpressing WT human tau | ALZ17 | 4R | Yes | Clavaguera et al., 2013 | |
| Mice overexpressing humanized MAPT in the absence of mouse tau | hTau | 3R > 4R | Yes | Hu et al., 2016 Miao et al., 2019 |
|
| Mice overexpressing all 6 human tau isoforms in the absence of mouse tau | 6hTau | 3R = 4R | Yes | He et al., 2020 Xu et al., 2021 |
|
| Amyloid mouse models | Mice expressing wild-type mouse tau | 5xFAD | No | He et al., 2018 Vergara et al., 2019 Xu et al., 2021 |
|
| APP KI | No | He et al., 2018 | |||
| Mice with targeted replacement of the mouse MAPT sequence | MAPT/APP double KI | 3R > 4R | No | Saito et al., 2019 | |